William Fairey

Direttore/Membro del Consiglio presso MIRUM PHARMACEUTICALS, INC.

Patrimonio netto: - $ in data 30/04/2024

60 anni

Health Technology

Consumer Services

Posizioni attive di William Fairey

Società	Posizione	Inizio	Fine
MIRUM PHARMACEUTICALS, INC.	Direttore/Membro del Consiglio	19/08/2021	-
MIRUM PHARMACEUTICALS, INC.	Independent Dir/Board Member	19/08/2021	-
ASCENDIS PHARMA A/S	Direttore/Membro del Consiglio	01/09/2022	-
ASCENDIS PHARMA A/S	Independent Dir/Board Member	01/09/2022	-
AILERON THERAPEUTICS, INC.	Direttore/Membro del Consiglio	31/10/2023	-
AILERON THERAPEUTICS, INC.	Independent Dir/Board Member	31/10/2023	-
KALVISTA PHARMACEUTICALS, INC.	Direttore/Membro del Consiglio	18/04/2024	-
Actelion Pharmaceuticals Trading (Shanghai) Co. Ltd.	Direttore/Membro del Consiglio	-	-
Respira Therapeutics, Inc. Respira Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Respira Therapeutics, Inc. engages in provision of pulmonary delivery of therapeutics for respiratory diseases. Its technology Dry Powder Inhaler (DPI), deliver dry powder drug products to the lung more effectively than other DPI technologies. The company was founded in 2010 and is headquartered in Albuquerque, NM.	Presidente	01/01/2022	-

Storia della carriera di William Fairey

Precedenti posizioni note di William Fairey

Società	Posizione	Inizio	Fine
Lung Therapeutics, Inc. Lung Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lung Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of drugs for lung injury and disease. Its product pipelines include LTI-03 for the treatment of Idiopathic Pulmonary Fibrosis and LTI-01 for Loculated Pleural Effusion. The company was founded by Steven Idell and Andrew Mazar in 2012 and is headquartered in Austin, TX.	Direttore/Membro del Consiglio	31/08/2021	31/10/2023
MYOKARDIA, INC.	Corporate Officer/Principal	01/01/2019	01/11/2020
CHEMOCENTRYX, INC.	Direttore operativo	08/01/2018	18/01/2019
░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░ ░░░░	░░░░░░░░░	░░░░░░░░░░	░░░░░░░░░░
░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░	░░░░░░░░░ ░░░░░░░░░░░░░░░░░	░░░░░░░░░░	░░░░░░░░░░
░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░░░ ░░░░	░░░░░░░░░	░░░░░░░░░░	░░░░░░░░░░
░░░░░░░░░ ░░░░ ░░░░░░░ ░░░░░░ ░░░░	░░░░░░░░░ ░░░░░░░░░░░░░░░░░	-	-

Formazione di William Fairey

St. Mary's College of California	Masters Business Admin
University of Oregon	Undergraduate Degree

Statistiche

Distribuzione geografica

Stati Uniti	11
Danimarca	2
Australia	2

Posizioni

Director/Board Member	6
Corporate Officer/Principal	3
Independent Dir/Board Member	3

Settori

Health Technology	11
Consumer Services	4

Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Società collegate

Società quotate in Borsa	4
AILERON THERAPEUTICS, INC.	Health Technology
ASCENDIS PHARMA A/S	Health Technology
KALVISTA PHARMACEUTICALS, INC.	Health Technology
MIRUM PHARMACEUTICALS, INC.	Health Technology

Aziende private	9
ChemoCentryx, Inc. ChemoCentryx, Inc. Pharmaceuticals: MajorHealth Technology ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in San Carlos, CA.	Health Technology
MyoKardia, Inc. MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA.	Health Technology
Lung Therapeutics, Inc. Lung Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lung Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of drugs for lung injury and disease. Its product pipelines include LTI-03 for the treatment of Idiopathic Pulmonary Fibrosis and LTI-01 for Loculated Pleural Effusion. The company was founded by Steven Idell and Andrew Mazar in 2012 and is headquartered in Austin, TX.	Health Technology
Actelion Pharmaceuticals US, Inc. Actelion Pharmaceuticals US, Inc. Pharmaceuticals: MajorHealth Technology Part of Johnson & Johnson, Actelion Pharmaceuticals US, Inc. is a company that manufactures, distributes and markets drugs. The company is based in Titusville, NJ. The CEO of the company is Samuele Butera.	Health Technology
Australia Asia Pacific Hotels Ltd. Australia Asia Pacific Hotels Ltd. Hotels/Resorts/Cruise linesConsumer Services Australia Asia Pacific Hotels Ltd. is an Australian private company located in Sydney. The firm operates hotels.	Consumer Services
Respira Therapeutics, Inc. Respira Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Respira Therapeutics, Inc. engages in provision of pulmonary delivery of therapeutics for respiratory diseases. Its technology Dry Powder Inhaler (DPI), deliver dry powder drug products to the lung more effectively than other DPI technologies. The company was founded in 2010 and is headquartered in Albuquerque, NM.	Health Technology
Actelion Pharmaceuticals Canada, Inc.
Actelion Pharmaceuticals Ltd. Actelion Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Johnson & Johnson, Actelion Pharmaceuticals Ltd. is a Swiss company that develops and distributes molecular weight drugs. The company is based in Allschwil, Switzerland.	Health Technology
Actelion Pharmaceuticals Trading (Shanghai) Co. Ltd.

Vedi le connessioni aziendali